Combating antimicrobial resistance: policy recommendations to save lives (Q24632857)

8

object named as

Dale Gerding

0 references

Martin J. Blaser

3

object named as

Martin Blaser

0 references

Fred C Tenover

14

object named as

Fred C Tenover

0 references

author name string

Brad Spellberg

2

0 references

Robert J Guidos

4

0 references

Helen W Boucher

5

0 references

John S Bradley

6

0 references

Barry I Eisenstein

7

0 references

L Barth Reller

10

0 references

John Rex

11

0 references

David Schwartz

12

0 references

Edward Septimus

13

0 references

David N Gilbert

Clinical Infectious Diseases

15

0 references

language of work or name

English

0 references

publication date

May 2011

0 references

published in

0 references

volume

52 Suppl 5

0 references

page(s)

S397-428

0 references

issue

Supplement 5

0 references

cites work

Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3738230

Significant reduction of antibiotic use in the community after a nationwide campaign in France, 2002-2007

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3738230

Estimating health care-associated infections and deaths in U.S. hospitals, 2002

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3738230

Resistance in Nonfermenting Gram-Negative Bacteria: Multidrug Resistance to the Maximum

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3738230

Duration of antibacterial treatment for uncomplicated urinary tract infection in women

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3738230

Antimicrobial agents for complicated skin and skin-structure infections: justification of noninferiority margins in the absence of placebo-controlled trials

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3738230

Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3738230

A comparative study on the cost of new antibiotics and drugs of other therapeutic categories

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3738230

Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: ethical and scientific issues

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3738230

The tragedy of the commons. The population problem has no technical solution; it requires a fundamental extension in morality

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3738230

Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3738230

Invasive methicillin-resistant Staphylococcus aureus infections in the United States

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3738230

Design of clinical trials of antibacterial agents for community-acquired bacterial pneumonia

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3738230

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3738230

Risk factors and treatment outcomes of community-onset bacteraemia caused by extended-spectrum beta-lactamase-producing Escherichia coli

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3738230

Detection of Enterobacteriaceae isolates carrying metallo-beta-lactamase - United States, 2010.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3738230

Cancer clinical trials--a chronic but curable crisis

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3738230

Use of plasma procalcitonin levels as an adjunct to clinical microbiology

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3738230

Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA).

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3738230

Clinical and economic outcomes attributable to health care-associated sepsis and pneumonia

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3738230

Attributable hospital cost and length of stay associated with health care-associated infections caused by antibiotic-resistant gram-negative bacteria

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3738230

Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3738230

Position paper: recommended design features of future clinical trials of antibacterial agents for community-acquired pneumonia

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3738230

Executive summary: workshop on issues in the design and conduct of clinical trials of antibacterial drugs in the treatment of community-acquired pneumonia

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3738230

Evaluation of a rapid antigen detection test in the diagnosis of streptococcal pharyngitis in children and its impact on antibiotic prescription

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3738230

Pseudomonas aeruginosa susceptible only to colistin in intensive care unit patients

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3738230

The research agenda of the National Institute of Allergy and Infectious Diseases for antimicrobial resistance

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3738230

Diagnosing streptococcal sore throat in adults: randomized controlled trial of in-office aids.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3738230

Clinical practice. Skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3738230

Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3738230

Limiting the emergence of extended-spectrum Beta-lactamase-producing enterobacteriaceae: influence of patient population characteristics on the response to antimicrobial formulary interventions

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3738230

Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3738230

Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3738230

Antibacterial drug discovery: is it all downhill from here?

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3738230

Emergence of carbapenem-resistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 beta-lactamases in New York City

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3738230

Why is big Pharma getting out of antibacterial drug discovery?

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3738230

The abandonment of antibacterials: why and wherefore?

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3738230

Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3738230

Trends in infectious disease mortality in the United States during the 20th century

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3738230

Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3738230

Effects of requiring prior authorization for selected antimicrobials: expenditures, susceptibilities, and clinical outcomes

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3738230

Scarlet fever and erysipelas in Norway during the last hundred years

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3738230

The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3738230

A national cancer clinical trials system for the 21st century: reinvigorating the NCI Cooperative Group Program

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3738230

The 10 x '20 Initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020.

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3738230

Increasing resistance of acinetobacter species to imipenem in United States hospitals, 1999-2006.

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3738230

Impact of rapid streptococcal test on antibiotic use in a pediatric emergency department.

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3738230

Risk factors for and clinical outcomes of bloodstream infections caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3738230

Controlled trials: the 1948 watershed

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3738230

Antibiotic resistance patterns during aminoglycoside restriction.

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3738230

Effects of a rapid antigen test for group A streptococcal pharyngitis on physician prescribing and antibiotic costs

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3738230

Looming Global-Scale Failures and Missing Institutions

30 May 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR153

International study of the prevalence and outcomes of infection in intensive care units

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR153

Excess costs and utilization associated with methicillin resistance for patients with Staphylococcus aureus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR153

Methicillin-ResistantS. aureusInfections among Patients in the Emergency Department

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR153

The growing menace of community-acquired methicillin-resistant Staphylococcus aureus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR153

Methicillin-resistant Staphylococcus aureus disease in three communities

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR153

Community-associated MRSA--resistance and virulence converge

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR153

National trends in ambulatory visits and antibiotic prescribing for skin and soft-tissue infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR153

Increasing occurrence of multidrug-resistance in Acinetobacter baumannii isolates from four German University Hospitals, 2002-2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR153

Global spread of carbapenem-resistant Acinetobacter baumannii

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR153

Nosocomial imipenem-resistant Acinetobacter baumannii infections: epidemiology and risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR153

Nosocomial outbreak of infection with pan-drug-resistant Acinetobacter baumannii in a tertiary care university hospital

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR153

Independent emergence of colistin-resistant Acinetobacter spp. isolates from Korea.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR153

Epidemiology and impact of imipenem resistance in Acinetobacter baumannii

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR153

Pandrug-resistant Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii infections: characteristics and outcome in a series of 28 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR153

Imipenem resistance among pseudomonas aeruginosa isolates: risk factors for infection and impact of resistance on clinical and economic outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR153

Resistance in gram-negative bacteria: Enterobacteriaceae.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR153

Urinary tract infection caused by fluoroquinolone- and cephem-resistant Enterobacteriaceae.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR153

Emergence and dissemination of extended-spectrum beta-lactamase-producing Escherichia coli in the community: lessons from the study of a remote and controlled population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR153

Community-onset bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: risk factors and prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR153

Dissemination of ST131 and ST393 community-onset, ciprofloxacin-resistant Escherichia coli clones causing urinary tract infections in Korea

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR153

Risk factors for extended-spectrum beta-lactamase positivity in uropathogenic Escherichia coli isolated from community-acquired urinary tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR153

Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR153

21 January 2018

tragedy of the commons

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR153

Telithromycin and the FDA: implications for the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR153

Management of acute pharyngitis in adults: reliability of rapid streptococcal tests and clinical findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR153

High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR153

Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR153

Procalcitonin Guidance of Antibiotic Therapy in Community-acquired Pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR153

Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR153

The FDA and the case of Ketek

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR153

Stoking the antibiotic pipeline.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3738230

Targeting persistence: the next frontier in TB drug development

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3738230

Social ramifications of control of microbial disease.

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3738230

The United States Food and Drug Administration and noninferiority margins in clinical trials of antimicrobial agents

28 November 2018

1 reference

12 December 2020

Hospital and Societal Costs of Antimicrobial‐Resistant Infections in a Chicago Teaching Hospital: Implications for Antibiotic Stewardship

1 reference

12 December 2020

The United States Food and Drug Administration and the end of antibiotics

1 reference

12 December 2020

Where does novel antibiotics R&D stand among other pharmaceutical products: an industrial perspective?

1 reference

12 December 2020

1 reference

12 December 2020

The treatment of pneumococcal meningitis

1 reference

12 December 2020

Ketek--the FDA perspective

1 reference

12 December 2020

Acute endocarditis due to Staphylococcus aureus successfully treated with penicillin

1 reference

12 December 2020

Penicillin in subacute bacterial endocarditis

1 reference

12 December 2020

Introducing Modern Medicine in a Navajo Community

1 reference

12 December 2020

Current issues in non-inferiority trials

1 reference

12 December 2020

Stimulating antibiotic development

1 reference

12 December 2020

Noninferiority and equivalence trials: deciphering 'similarity' of medical interventions

1 reference

12 December 2020

RANDOMISED TRIAL OF INTRAVENOUS STREPTOKINASE, ORAL ASPIRIN, BOTH, OR NEITHER AMONG 17 187 CASES OF SUSPECTED ACUTE MYOCARDIAL INFARCTION: ISIS-2

1 reference

12 December 2020

Development of new antibacterials: a laudable aim, but what is the value?

1 reference

12 December 2020

Identifiers

DOI

10.1093/CID/CIR153

1 reference

1659014

1659014

1 reference

1 reference

1 reference